Therefore, DTC with TERT promoter mutations present aggressively clinical behaviors, and TERT promoter mutations could be considered as biomarkers assisting in risk stratification, prognostic prediction, and individualizing therapeutic options for DTC (PTC and FTC). This evidence concerns the gene TERT and thyroid cancer, nonmedullary, 2.